Bausch + Lomb to Pay $1.75B for Eye Drug From Novartis
Portfolio Pulse from Charles Gross
Bausch + Lomb, a subsidiary of Bausch Health Companies Inc. (BHC), has agreed to pay $1.75 billion to acquire an eye drug from Novartis AG (NVS).
June 30, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bausch Health's subsidiary Bausch + Lomb is acquiring an eye drug from Novartis for $1.75 billion.
The acquisition could potentially strengthen Bausch Health's portfolio in the eye care sector. However, the financial impact of the acquisition on Bausch Health's short-term stock performance is uncertain.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Novartis AG is selling an eye drug to Bausch + Lomb for $1.75 billion.
The sale could potentially streamline Novartis' portfolio and provide additional capital. However, the financial impact of the sale on Novartis' short-term stock performance is uncertain.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100